Acylated glucagon analogues
US10004786B2 · kind B2 · utility
11Cited by
10References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 2, 2015 |
| Grant date | Jun 26, 2018 |
| Priority date | — |
| Expiry date | Sep 2, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/605
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.